Pharma giants announce diabetes drug partnership

04/29/2013 | PharmaLive.com

Merck and Pfizer announced plans to combine Merck's DPP-4 inhibitor Januvia with Pfizer's SGLT-2 inhibitor ertugliflozin to treat type 2 diabetes. Merck paid Pfizer $60 million and will split costs and revenue 60-40 with Pfizer. "This is like the Yankees and Red Sox combining their scouting departments," former Pfizer research chief John LaMattina wrote on Twitter, but Diabetic Investor publisher David Kliff said the resulting drug will be just "another tool in the toolbox."

View Full Article in:

PharmaLive.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Compliance and Ethics Director
Sysmex America, Inc.
Lincolnshire, IL
Director, Site Quality Management
CareFusion
Palm Springs, CA
Compliance Officer-Medical Products
W. L. Gore
Flagstaff, AZ
Project Manager RA - 15000003MD
Abbott
Santa Clara, CA
Director, Site Quality Management
CareFusion
Minneapolis, MN